Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune

American Journal of Transplantation

Volumn 2, Issue 1, 2002, Pages 100-104

  Meier Kriesche, Herwig Ulf ^a   Kaplan, Bruce ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cyclosporine; Graft survival; Tacrolimus; Transplantation

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALLOGRAFT; ARTICLE; CAUCASIAN; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DATA BASE; DEMOGRAPHY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEMODIALYSIS; HLA MATCHING; HUMAN; INFECTION; ISCHEMIA; KAPLAN MEIER METHOD; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MICROEMULSION; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; STATISTICAL ANALYSIS; SURVIVAL RATE; THROMBOSIS;

ADULT; CHEMISTRY, PHARMACEUTICAL; COMPARATIVE STUDY; CYCLOSPORINE; EMULSIONS; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 0036460895     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.020116.x     Document Type: Article

References (16)

1. Kahan BD, Dunn J, Fitts C et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505-511.
2. Kovarik JM, Mueller EA, van Bree JB et al. Cyclosporine pharmaco-kinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-663.
3. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444-446.
4. Kahan BD, Welsh M, Urbauer DL et al. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol 2000; 11: 1122-1131.
5. Shah MB, Martin JE, Schroeder TJ, First MR. The evaluation of the safety and tolerability of two formulations of cyclosporine: NEORAL and sandimmune. A meta-analysis. Transplantation 1999; 67: 1411-1417.
6. Pollard SG, Lear PA, Ready AR, Moore RH, Johnson RW. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. NEORAL Renal Study Group. Transplantation 1999; 68: 1325-1331.
7. Fung JJ, Starzl TE. FK506 in solid organ transplantation. Ther Drug Monit 1995; 17: 592-595.
8. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (NEORAL) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-841.
9. White SA, Jain S, Williams ST et al. Randomized trial comparing NEORAL and tacrolimus immunousuppression for recipients of renal transplants procured from different donor groups. Transplant Proc 2000; 32: 600.
10. Hauser IA, Neumayer HN. Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation. European Multicentre Tacrolimus (FK506) Renal Study Group. Transpl Int 1998; 11 (Suppl. 1): S73-77.
11. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1216-1218.
12. Morris-Stiff G, Ostrowski K, Balaji V et al. Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. Transpl Int 1998; 11 (Suppl. 1): S334-336.
13. Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443.
14. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group [see comments]. Transplantation 1997: 63: 977-983.
15. Shield CF III, McGrath MM, Goss TF. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. Transplantation 1997; 64: 1738-1743.
16. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-2409.